Nature Communications (Jul 2021)
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
- Pedro M. Folegatti,
- Kate Harrison,
- Lorena Preciado-Llanes,
- Fernando Ramos Lopez,
- Mustapha Bittaye,
- Young Chan Kim,
- Amy Flaxman,
- Duncan Bellamy,
- Rebecca Makinson,
- Jonathan Sheridan,
- Sasha R. Azar,
- Rafael Kroon Campos,
- Mark Tilley,
- Nguyen Tran,
- Daniel Jenkin,
- Ian Poulton,
- Alison Lawrie,
- Rachel Roberts,
- Eleanor Berrie,
- Shannan L. Rossi,
- Adrian Hill,
- Katie J. Ewer,
- Arturo Reyes-Sandoval
Affiliations
- Pedro M. Folegatti
- The Jenner Institute, University of Oxford
- Kate Harrison
- The Jenner Institute, University of Oxford
- Lorena Preciado-Llanes
- The Jenner Institute, University of Oxford
- Fernando Ramos Lopez
- The Jenner Institute, University of Oxford
- Mustapha Bittaye
- The Jenner Institute, University of Oxford
- Young Chan Kim
- The Jenner Institute, University of Oxford
- Amy Flaxman
- The Jenner Institute, University of Oxford
- Duncan Bellamy
- The Jenner Institute, University of Oxford
- Rebecca Makinson
- The Jenner Institute, University of Oxford
- Jonathan Sheridan
- The Jenner Institute, University of Oxford
- Sasha R. Azar
- Department of Pathology, University of Texas Medical Branch
- Rafael Kroon Campos
- Department of Microbiology and Immunology, University of Texas Medical Branch
- Mark Tilley
- The Jenner Institute, University of Oxford
- Nguyen Tran
- The Jenner Institute, University of Oxford
- Daniel Jenkin
- The Jenner Institute, University of Oxford
- Ian Poulton
- The Jenner Institute, University of Oxford
- Alison Lawrie
- The Jenner Institute, University of Oxford
- Rachel Roberts
- The Jenner Institute, University of Oxford
- Eleanor Berrie
- Clinical Bio-manufacturing Facility, University of Oxford
- Shannan L. Rossi
- Department of Pathology, University of Texas Medical Branch
- Adrian Hill
- The Jenner Institute, University of Oxford
- Katie J. Ewer
- The Jenner Institute, University of Oxford
- Arturo Reyes-Sandoval
- The Jenner Institute, University of Oxford
- DOI
- https://doi.org/10.1038/s41467-021-24906-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 10
Abstract
Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that has caused outbreaks in various regions of the world. Here the authors present safety and immunogenicity data from a phase 1 trial with the simian adenovirus vectored vaccine ChAdOx1 Chik, showing induction of neutralizing antibodies to four CHIKV lineages.
